AnaBios

AnaBios announced that Gatehouse Bio Chief Executive Officer Dr. David W. Salzman won its 2024 Translational Research Grant Award. The award provides up to $15,000.

AnaBios offers careers focused on advancing human-relevant science and translational research.

Andre Ghetti, PhD, is CEO of AnaBios. He previously led AVIVA Biosciences’ growth into drug discovery services and intellectual property commercialization and worked on drug discovery programs at Aurora Biosciences.

Charles Chesnutt is a global chief financial officer who has held executive roles at S&V Labs and IQinVision. Charles Chesnutt recently led S&V Labs through a period of growth and transition that resulted in a merger and acquisition process.

AnaBios Chief Commercial Officer Chris Mathes leads business development activities and contributes to the company’s strategic direction. Mathes previously served as CCO of Icagen.

AnaBios offers early human insights into drug development and applies its knowledge of human tissue procurement and utilization.

Everyone at AnaBios shares a passion and commitment to make a difference in the development of promising new therapies and cures for patients.

AnaBios invites inquiries about human tissue and cells, cardiac and pain research assays, and pricing through its contact form.

AnaBios provides high quality human tissue and cells, including heart, lung and dorsal root ganglia, for drug discovery & academic research.